TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36314032

Group type: EXPERIMENTAL
Intervention: Active + MM (anodal tDCS + mindfulness meditation)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham + MM (sham tDCS + mindfulness meditation)
Number of subjects: 30

Group type: COMPARATOR
Intervention: NoT (no intervention)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Active + MM
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham + MM
Number of subjects: 30

Group type: COMPARATOR
Intervention: NoT
Number of subjects: 30
Study: 32702309

Group type: EXPERIMENTAL
Intervention: Pazopanib (350 mg/m2 once daily for patients <18 years; 600 mg once daily for patients ≥18 years)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (no pazopanib)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Pazopanib and Control
Number of subjects: 81
Study: 36369034

Group type: EXPERIMENTAL
Intervention: Robotic-assisted laparoscopic (RAL) Heller myotomy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Laparoscopic (LSC) Heller myotomy
Number of subjects: 43
Study: 33335310

Group type: EXPERIMENTAL
Intervention: JNJ-42165279 (100 mg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 32867830

Group type: EXPERIMENTAL
Intervention: Prescription of biotherapy (rituximab, adalimumab, abatacept) using SinnoTest® software, a prediction software based on proteomic biomarkers.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prescription of biotherapy based on current practice, without the SinnoTest® software (any biotherapy).
Number of subjects: 0
Study: 33543797

Group type: EXPERIMENTAL
Intervention: Energy-dense formula (100 mL, 2 kcal/mL)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard formula (200 mL, 1 kcal/mL)
Number of subjects: 18
Study: 33290192

Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (breast milk)
Number of subjects: 120
Study: 33248560

Group type: EXPERIMENTAL
Intervention: DTUMV + dIL-2
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 1/2DTUMV + dIL-2
Number of subjects: 55

Group type: COMPARATOR
Intervention: DTUMV
Number of subjects: 55

Group type: COMPARATOR
Intervention: 1/2DTUMV
Number of subjects: 55

Group type: COMPARATOR
Intervention: PBS
Number of subjects: 55
Study: 36307059

Group type: EXPERIMENTAL
Intervention: Isavuconazole
Number of subjects: 103

Group type: COMPARATOR
Intervention: Voriconazole
Number of subjects: 103
Study: 33600539

Group type: EXPERIMENTAL
Intervention: Abutment screws retightened 10 minutes after initial torque application
Number of subjects: 158

Group type: COMPARATOR
Intervention: Abutment screws not retightened 10 minutes after initial torque application
Number of subjects: 158
Study: 32506227

Group type: EXPERIMENTAL
Intervention: FTL-assisted delivery of topical tranexamic acid (TXA)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Normal saline solution (NSS)
Number of subjects: 46
Study: 36313769

Group type: EXPERIMENTAL
Intervention: Nutritional intervention based on a Mediterranean diet (IG)
Number of subjects: 2418

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 2418

Group type: EXPERIMENTAL
Intervention: Nutritional intervention group (IG)
Number of subjects: 2418

Group type: EXPERIMENTAL
Intervention: Real-world group (RW)
Number of subjects: 2418

Group type: EXPERIMENTAL
Intervention: Caucasian variants
Number of subjects: 2418

Group type: EXPERIMENTAL
Intervention: Hispanic variants
Number of subjects: 2418
Study: 32868704

Group type: EXPERIMENTAL
Intervention: Chest X-ray examination (AP and PA projections)
Number of subjects: 240
Study: 35940932

Group type: EXPERIMENTAL
Intervention: Antibacterial hand sanitizer
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Iodophor solution
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 34161360

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) and solifenacin succinate
Number of subjects: 86

Group type: COMPARATOR
Intervention: Solifenacin succinate alone
Number of subjects: 86
Study: 35613402

Group type: EXPERIMENTAL
Intervention: Reiki sessions conducted by trained and experienced Reiki masters, lasting between 45 and 90 minutes.
Number of subjects: 1284
Study: 33882779

Group type: EXPERIMENTAL
Intervention: Simulated visual acuity (VA) impairments
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Simulated contrast sensitivity (CS) impairments
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Simulated visual field (VF) impairments
Number of subjects: 33

Group type: COMPARATOR
Intervention: Clear goggle (no impairment) trials
Number of subjects: 33
Study: 34602386

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (DCB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 50
Study: 34766389

Group type: EXPERIMENTAL
Intervention: M. officinalis capsules (400 mg/d; n = 23)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (n = 26)
Number of subjects: 49
Study: 35505375

Group type: EXPERIMENTAL
Intervention: Umbilical cord-derived mesenchymal stem cells (UC-MSCs)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 32940750

Group type: EXPERIMENTAL
Intervention: Short-arm fiberglass cast (SAC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Long-arm cast (LAC)
Number of subjects: 120
Study: 35041636

Group type: EXPERIMENTAL
Intervention: Hydrocodone/acetaminophen 5/325 mg
Number of subjects: 347

Group type: COMPARATOR
Intervention: Ibuprofen/acetaminophen 600/325 mg
Number of subjects: 347
Study: 33197662

Group type: EXPERIMENTAL
Intervention: Peppermint oil applied three times a day for five days after chemotherapy in addition to routine antiemetic treatment.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine antiemetic treatment only (Control group).
Number of subjects: 0
Study: 35870902

Group type: EXPERIMENTAL
Intervention: Nebulized budesonide combined with intravenous hydrocortisone hemisuccinate (n = 23)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline combined with intravenous hydrocortisone hemisuccinate (n = 27)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (budesonide and control)
Number of subjects: 50
Study: 33683070

Group type: EXPERIMENTAL
Intervention: Clindamycin 1%-Tretinoin 0.025% (CT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Benzoyl Peroxide 2.5%-Adapalene 0.1% (BA)
Number of subjects: 20
Study: 34498068

Group type: EXPERIMENTAL
Intervention: 1 g IV acetaminophen every six hours for 48 hours postoperatively
Number of subjects: 154

Group type: COMPARATOR
Intervention: IV placebo every six hours for 48 hours postoperatively
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: 1 g IV acetaminophen
Number of subjects: 154

Group type: COMPARATOR
Intervention: IV placebo
Number of subjects: 154
Study: 35866206

Group type: EXPERIMENTAL
Intervention: Telephone delivered intervention (seven telephone calls, fortnightly, plus a booster session at 16 weeks)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Information only (control group)
Number of subjects: 76
Study: 33223538

Group type: EXPERIMENTAL
Intervention: Work Ability Index
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: WHO Disability Assessment Schedule 2.0
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: WHO Quality of Life-BREF questionnaire
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Musculoskeletal and cardiovascular diseases
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Adaptation of the workplace to functional and health-related needs
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Psychological well-being
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Cognitive performance
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Number of chronic diseases
Number of subjects: 201
Study: 32079342

Group type: EXPERIMENTAL
Intervention: Exercise group (EG) following the SWEP method
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 129
Study: 35818157

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy for pollen; 3 years of treatment.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy for grass pollen, house-dust mite, or Japanese cedar; duration not specified.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both sublingual and subcutaneous grass pollen immunotherapies; 2 years of treatment.
Number of subjects: 10
Study: 33602945

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 35636467

Group type: EXPERIMENTAL
Intervention: Surgical masks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: FFP2 masks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Baseline (no mask)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Post-baseline (no mask)
Number of subjects: 45
Study: 33766760

Group type: EXPERIMENTAL
Intervention: Stepped care model of psychological care (low intensity CBT program: Internet-delivered or work-at-home book with brief therapist calls)
Number of subjects: 666
Study: 36364765

Group type: EXPERIMENTAL
Intervention: Drinking speed of 20 mL/5 min
Number of subjects: 18

Group type: COMPARATOR
Intervention: Drinking speed of 40 mL/5 min
Number of subjects: 18

Group type: COMPARATOR
Intervention: Drinking speed of 80 mL/5 min
Number of subjects: 18
Study: 32653359

Group type: EXPERIMENTAL
Intervention: White noise
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Recorded mother's voice
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: MiniMuffs
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control
Number of subjects: 64
Study: 34218069

Group type: EXPERIMENTAL
Intervention: e-book (n=33)
Number of subjects: 66

Group type: COMPARATOR
Intervention: video and brochure (n=33)
Number of subjects: 66
Study: 32580063

Group type: EXPERIMENTAL
Intervention: Wearing a strapped standard helmet
Number of subjects: 479892

Group type: EXPERIMENTAL
Intervention: Wearing an unstrapped standard helmet
Number of subjects: 479892
Study: 34536404

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 496

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 496
Study: 34428832

Group type: EXPERIMENTAL
Intervention: Vancomycin (7 days of oral intake)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 43
Study: 36005837

Group type: EXPERIMENTAL
Intervention: BREAK (interrupting 4 hr of sitting with 4 min of light body‐weighted resistance activity every 30‐min)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: BREAK
Number of subjects: 17

Group type: COMPARATOR
Intervention: SIT (4 hr of uninterrupted sitting)
Number of subjects: 17

Group type: COMPARATOR
Intervention: SIT
Number of subjects: 17
Study: 33942989

Group type: EXPERIMENTAL
Intervention: Patient group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 36455058

Group type: EXPERIMENTAL
Intervention: MD/DO
Number of subjects: 126

Group type: COMPARATOR
Intervention: DO/DO
Number of subjects: 126

Group type: COMPARATOR
Intervention: MD/MD
Number of subjects: 126
Study: 33093119

Group type: EXPERIMENTAL
Intervention: FP-SAL
Number of subjects: 2652
Study: 34047697

Group type: EXPERIMENTAL
Intervention: Nomogram140/90
Number of subjects: 6201

Group type: EXPERIMENTAL
Intervention: Nomogram130/80
Number of subjects: 6201
Study: 32565594

Group type: EXPERIMENTAL
Intervention: Vilazodone 20 mg daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Escitalopram 20 mg daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Amitriptyline 75 mg daily
Number of subjects: 30
Study: 36367768

Group type: EXPERIMENTAL
Intervention: Transverse incision
Number of subjects: 136

Group type: COMPARATOR
Intervention: Longitudinal incision
Number of subjects: 136
Study: 33560411

Group type: EXPERIMENTAL
Intervention: i.v. ghrelin administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 0
Study: 32809002

Group type: EXPERIMENTAL
Intervention: Collaborative care model (12 months of self-management support, decision support electronic health records, specialist case reviews)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Usual care (24 months)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Collaborative care model
Number of subjects: 404

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 404
Study: 35586130

Group type: EXPERIMENTAL
Intervention: Paraformaldehyde based pulpal medicament
Number of subjects: 82
Study: 33704530

Group type: EXPERIMENTAL
Intervention: lenalidomide
Number of subjects: 41

Group type: COMPARATOR
Intervention: standard induction chemotherapy
Number of subjects: 41
Study: 33039693

Group type: EXPERIMENTAL
Intervention: Semaglutide (0.1 mg, 0.2 mg, 0.4 mg)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 320
Study: 35362776

Group type: EXPERIMENTAL
Intervention: Antecedent-based techniques (n = 26)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Consequent-based techniques (n = 25)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Waitlist control condition (n = 23)
Number of subjects: 74
Study: 33384215

Group type: EXPERIMENTAL
Intervention: Labeled surgical caps
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonlabeled surgical caps
Number of subjects: 20
Study: 33002704

Group type: EXPERIMENTAL
Intervention: Anx/Dep+CB group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Anx/Dep-lowCB group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Stop Signal Task (SST)
Number of subjects: 42
Study: 35775365

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 33322936

Group type: EXPERIMENTAL
Intervention: Unstable Training Group (UTG)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Stable Training Group (STG)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 77
Study: 33573854

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgical (MIS) staging
Number of subjects: 254
Study: 36059000

Group type: COMPARATOR
Intervention: Copy number alterations
Number of subjects: 300

Group type: COMPARATOR
Intervention: Copy number loss
Number of subjects: 300

Group type: COMPARATOR
Intervention: Loss of segments in chromosome 5q21‐22 and gains at 8q21‐24
Number of subjects: 300

Group type: COMPARATOR
Intervention: Variability of copy number alterations across tumour regions
Number of subjects: 300
Study: 34363051

Group type: EXPERIMENTAL
Intervention: Home-based transcutaneous electrical acupoint stimulation (TEAS) for 12 weeks, 4 weekly sessions
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (continuation of antihypertensive drugs and lifestyle education)
Number of subjects: 60
Study: 32639394

Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate (KF) 5 mg orally twice daily for 6 weeks
Number of subjects: 151

Group type: COMPARATOR
Intervention: Lactose placebo (PL) orally twice daily for 6 weeks
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Operative management
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Nonoperative management
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate (KF)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Lactose placebo (PL)
Number of subjects: 151
Study: 34186535

Group type: EXPERIMENTAL
Intervention: Exercise (part of a randomized controlled trial)
Number of subjects: 462
Study: 33217860

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 108
Study: 35081130

Group type: EXPERIMENTAL
Intervention: Blended Acceptance and Commitment Therapy (ACT)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 314
Study: 33582687

Group type: EXPERIMENTAL
Intervention: Cilnidipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 0
Study: 35578403

Group type: EXPERIMENTAL
Intervention: Sleep continuity disruption (n = 27)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Uninterrupted sleep (n = 24)
Number of subjects: 51
Study: 34737470

Group type: EXPERIMENTAL
Intervention: Intervention arm (n=1987)
Number of subjects: 4108

Group type: COMPARATOR
Intervention: Control arm (n=1966)
Number of subjects: 4108
Study: 35584530

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) experience during cystoscopy
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group (no VR experience)
Number of subjects: 159
Study: 33653754

Group type: EXPERIMENTAL
Intervention: Vibration therapy coupled with protocolised mobilisation
Number of subjects: 188

Group type: COMPARATOR
Intervention: Protocolised mobilisation alone
Number of subjects: 188
Study: 32024955

Group type: EXPERIMENTAL
Intervention: Osmotically controlled Eperisone 150 mg tablets
Number of subjects: 12

Group type: COMPARATOR
Intervention: Immediate release Eperisone tablets (reference formulation)
Number of subjects: 12
Study: 34567486

Group type: EXPERIMENTAL
Intervention: Comprehensive nursing intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional nursing intervention
Number of subjects: 0
Study: 33239951

Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning (IPC)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Active Recovery (AR)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Neuromuscular Electrical Stimulation (NMES)
Number of subjects: 9
Study: 34691212

Group type: EXPERIMENTAL
Intervention: DHEA (25 mg orally 3 times a day for 90 days)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 34327587

Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Diseased individuals
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Rural individuals
Number of subjects: 250

Group type: COMPARATOR
Intervention: Urban individuals
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Sample randomization algorithm
Number of subjects: 250
Study: 32599738

Group type: EXPERIMENTAL
Intervention: Cereal A (0% whole grain flour, high sugar content, 24 g/100 g)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Cereal B (50% whole grain flour, medium sugar content, 12 g/100 g)
Number of subjects: 46
Study: 33795476

Group type: EXPERIMENTAL
Intervention: Alcoholic beverages
Number of subjects: 121

Group type: COMPARATOR
Intervention: Soda water
Number of subjects: 121
Study: 32777383

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin treatment for 24 weeks
Number of subjects: 290

Group type: COMPARATOR
Intervention: Matched placebo for 24 weeks
Number of subjects: 290
Study: 35412654

Group type: EXPERIMENTAL
Intervention: Moisturizer application to the perianal area
Number of subjects: 118

Group type: COMPARATOR
Intervention: Care without application of moisturizer to the perianal area
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Moisturizer application
Number of subjects: 118
Study: 32680742

Group type: EXPERIMENTAL
Intervention: Preoperative physiotherapy (information booklet and 30-minute face-to-face session with a physiotherapist)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Control group (information booklet only)
Number of subjects: 441
Study: 35981270

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (modified folinic acid-fluorouracil-oxaliplatin 6 or capecitabine-oxaliplatin) for 3 months followed by transanal excision surgery (TES)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Observation after declining TME surgery
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Transanal excision surgery (TES) after chemotherapy
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 1-year locoregional relapse-free survival
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 2-year locoregional relapse-free survival
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Quality of life and rectal function scores
Number of subjects: 58
Study: 34086194

Group type: EXPERIMENTAL
Intervention: Enteral nutrition (EN) refeeding protocol of 20 kcal/kg/day, reaching energy goals within 3 days
Number of subjects: 85

Group type: COMPARATOR
Intervention: Cautious refeeding protocol of 10 kcal/kg/day, reaching goals within 7 days
Number of subjects: 85
Study: 32187464

Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir (400 mg and 100 mg, respectively) twice a day for 14 days, in addition to standard care
Number of subjects: 199

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 199
Study: 36242050

Group type: EXPERIMENTAL
Intervention: Revitive Medic© Program 1
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Revitive® Program 2
Number of subjects: 3

Group type: COMPARATOR
Intervention: Revitive sham
Number of subjects: 3
Study: 34772742

Group type: EXPERIMENTAL
Intervention: Editorial intervention to reduce spin in the abstract's conclusion of manuscripts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32558330

Group type: EXPERIMENTAL
Intervention: Moderate hypocaloric Mediterranean diet
Number of subjects: 87

Group type: COMPARATOR
Intervention: Usual care (standard paediatric recommendations)
Number of subjects: 87
Study: 36471427

Group type: EXPERIMENTAL
Intervention: Intraosseous computerised anaesthesia (ICA) using QuickSleeper™ system
Number of subjects: 72

Group type: COMPARATOR
Intervention: Inferior alveolar nerve block anaesthesia (IANB)
Number of subjects: 72
Study: 36245373

Group type: EXPERIMENTAL
Intervention: CSO-PVS severity (moderate or frequent/severe)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CSO-PVS (moderate or frequent/severe)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CSO-PVS and time (follow-up)
Number of subjects: 0
Study: 35465733

Group type: EXPERIMENTAL
Intervention: alpelisib + trastuzumab (HR-negative cohort)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: alpelisib + trastuzumab + fulvestrant (HR-positive cohort)
Number of subjects: 300

Group type: COMPARATOR
Intervention: trastuzumab + chemotherapy (eribuline, capecitabine or vinorelbine)
Number of subjects: 300